1	Title						
2	Health Utility Value of Overactive Bladder in Japanese Older Adults						
3							
4	Authors and affiliations						
5	Takashi Yoshioka, MD, PhD <sup>1,2*</sup>						
6	Kenji Omae, MD, DrPH <sup>3,4</sup>						
7	Satoshi Funada, MD, PhD <sup>1</sup>						
8	Tetsuji Minami, MD, PhD <sup>5</sup>						
9	Rei Goto, MD, PhD <sup>6,7</sup>						
10							
11	<sup>1</sup> Health Technology Assessment Unit, Department of Preventive Medicine and Public Health,						
12	Keio University School of Medicine, Tokyo, Japan						
13	<sup>2</sup> Institute of Clinical Epidemiology, Showa University, Tokyo, Japan						
14	<sup>3</sup> Department of Innovative Research and Education for Clinicians and Trainees (DiRECT),						
15	Fukushima Medical University Hospital, Fukushima, Japan						
16	<sup>4</sup> Department of Health Promotion and Human Behavior, Graduate School of						
17	Medicine/School of Public Health, Kyoto University, Kyoto, Japan						
18	<sup>5</sup> Division of Quality Assurance Programs, Institute for Cancer Control, National Cancer						
19	Center, Tokyo, Japan						
20	<sup>6</sup> Graduate School of Health Management, Keio University, Kanagawa, Japan						
21	<sup>7</sup> Graduate School of Business Administration, Keio University, Kanagawa, Japan						
22							
23	*Corresponding author						
24	Takashi Yoshioka						
25	Health Technology Assessment Unit, Department of Preventive Medicine and Public Health,						
26	Keio University School of Medicine, Tokyo, Japan						
27	35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan						
28	Tel:+81-3-5363-3205						
29	E-mail: ty5733@keio.jp						

- 31 E-mail address:
- 32 Takashi Yoshioka, ty5733@keio.jp
- 33 Kenji Omae, oranz416@gmail.com
- 34 Satoshi Funada, sfunada@keio.jp
- 35 Tetsuji Minami, t.minami.for.urology@gmail.com
- 36 Rei Goto, reigoto@kbs.keio.ac.jp

37

- **38 Word counts:** 3,324
- **39** Number of Tables: 3
- 40 Number of Figures: 3
- 41 Number of References: 30

43	Abstract						
44	<b>Objectives:</b> To determine the health utility values (HUVs) of overactive bladder (OAB)						
45	among adults aged $\geq$ 65 years and to assess the HUV decrements (disutilities) of OAB						
46	according to its severity.						
47	Methods: This cross-sectional Internet-based study was conducted between 2 and 9						
48	November 2023, with quota sampling with equal probability for each gender and age group						
49	(age 65–74 years and $\geq$ 75 years). OAB was defined as an urgency score of $\geq$ 2 points and a						
50	total score of $\geq$ 3 points based on the Overactive Bladder Symptom Score. OAB severity was						
51	categorized as mild (total score, $\leq 5$ points) or moderate-to-severe (total score, 6–15 points).						
52	HUVs were measured using the EuroQol 5-Dimension 5-Level value set for the Japanese						
53	population. Multivariable linear regression models were fitted to estimate the						
54	covariate-adjusted disutilities of OAB, with eight covariates selected based on previous						
55	studies.						
56	<b>Results:</b> Among the 998 participants (51.9% male; mean age, 73.2 years), 158 (15.9%) had						
57	OAB, of whom 87 (8.8%) had moderate-to-severe OAB. The mean HUVs for participants						
58	with mild and moderate-to-severe OAB were 0.874 and 0.840, respectively, which were						
59	lower compared with the HUV for those without OAB (0.913). After adjusting for relevant						
60	covariates, disutilities (95% confidence intervals [CIs]) for mild and moderate-to-severe						
61	OAB were -0.0334 (-0.0602 to -0.0066) and -0.0591 (-0.0844 to -0.0339), respectively.						
62	<b>Conclusions:</b> This study examined HUVs in older Japanese adults with and without OAB.						
63	The results demonstrate that increased OAB severity is associated with greater disutility.						

- 64
- 65

# 66 Keywords:

- 67 Overactive bladder; lower urinary tract symptoms; health utility; health-related quality of life;
- 68 health economic evaluation

69

### 71 Introduction

72 Overactive bladder (OAB), characterized by urinary urgency with or without urgent urinary 73 incontinence, is associated with a substantial disease burden and significant economic impact 74 [1]. The extensive disease burden of OAB includes a decrease in health-related quality of life 75 (HRQoL), mood disorders, and various comorbid or consequential conditions (e.g. 76 constipation, fecal incontinence, and irritable bowel syndrome) [2]. The prevalence of OAB 77 increases with age [3]. Furthermore, evidence has demonstrated a longitudinal association 78 between OAB or its treatment with anticholinergics and an increased risk of falls, which are 79 the most critical outcomes in older adults [4]. Consequently, patients with OAB have higher 80 healthcare resource utilization than those without the condition, which contributes to a 81 substantial economic burden [5]. The high global prevalence of OAB, estimated at 15.5% 82 between 2007 and 2020, and its high healthcare cost of \$82.6 billion by 2020 in the United 83 States [1, 6] have drawn significant attention from both policymakers and clinicians 84 worldwide. 85 OAB is widely managed in various healthcare settings, including primary care, 86 urology, and urogynecology [7]. Treatment options for OAB include behavioral therapy and 87 pharmacotherapy, such as antimuscarinic and  $\beta$ -adrenergic agents [7]. Surgical treatments are 88 available for refractory cases, including intradetrusor injection of onabotulinum toxin A, 89 sacral neuromodulation, and percutaneous tibial nerve stimulation [7]. Although these 90 therapeutic options have the potential to relieve patients' symptoms and improve their

91 HRQoL, they also raise concerns about the increasing economic burden on healthcare

92 systems owing to higher treatment costs. Consequently, the importance of effectively

93 allocating finite healthcare resources for the management of OAB is becoming increasingly

94 recognized. In fact, the National Institute for Health and Care Excellence (NICE), an

95 independent organization providing evidence-based guidance to inform healthcare decisions

96 in the United Kingdom (UK), is currently conducting a health economic evaluation (HEE) of

97 vibegron [8], a novel  $\beta$ 3-adrenergic agonist with fewer antimuscarinic side effects compared

98 with traditional OAB medications [9]. Considering the example of the NICE in the UK, new

6

99 medical technologies for OAB, such as vibegrons, may also be subject to HEEs in other100 countries, such as Japan.

101	To make HEEs useful for policy decision-making, it is essential to assess their clinical					
102	effectiveness (e.g. quality-adjusted life years [QALYs]) using generic measures that can be					
103	collected for any disease. QALYs are calculated based on health utility values (HUVs)					
104	measured using generic preference-based measures (PBMs) rather than disease-specific ones					
105	[10]. Importantly, according to the NICE technology appraisal guidance, HUVs should be					
106	calculated using the EuroQoL 5-dimensions (EQ-5D), with data collected directly from					
107	patients in the country where the evaluation is being conducted (in the case of NICE, the UK)					
108	[11]. Previous studies have evaluated the association between OAB symptoms and HUVs					
109	using EQ-5D scores in the United States, United Kingdom, Spain, and South Korea [12–14].					
110	However, these studies have utilized the older version of the EQ-5D, the three-level EQ-5D					
111	version (EQ-5D-3L), which raises concerns about the potential overestimation of positive					
112	effects and underestimation of negative effects [15]. The newer version of the EQ-5D, the					
113	five-level EQ-5D version (EQ-5D-5L), was developed to overcome the ceiling effects and					
114	low sensitivity inherent in EQ-5D-3L [16]. Ideally, the estimation of HUVs based on					
115	EQ-5D-5L is essential. However, few studies have used this instrument.					
116	To address the unmet needs of global policies regarding HEEs of OAB, this study					
117	aimed to describe the HUVs of patients with OAB and assess the impacts of OAB on HUVs					
118	using EQ-5D-5L among older adults, the most vulnerable and policy-relevant subgroup,					

119 using an Internet-based survey.

120

### 121 Participants and methods

122 Study design and participants

123 This cross-sectional study was conducted as part of a research project aimed at developing an

124 EQ-5D-5L value set for the Japanese general older adults [16]. To obtain responses from a

sample of older adults, we used a sampling method that ensured a 1:1 ratio for both sex and

126 age groups (age 65–74 and  $\geq$ 75 years). The target sample size was 1,000 participants. The

127 sampling strategy and sample size were determined based on a previous study [17]. All

128	participants were recruited from a survey panel provided by a Japanese Internet research					
129	agency (Intage, Inc., https://www.intage.co.jp/english/) with approximately 2.6 million					
130	panelists and their demographic information. The survey was conducted between 2 and 9					
131	November 2023. We designed the survey to prevent participants from proceeding to the nex					
132	question without providing a valid response, thereby eliminating missing data. The survey					
133	questionnaire and response options are presented in Method S1.					
134						
135	Inclusion and exclusion criteria					
136	All respondents were included in the analysis. However, participants who responded 'prefer					
137	not to answer' to at least one of the questionnaires except for income items were excluded					
138	from this study.					
139						
140	Exposures (overactive bladder)					
141	The variable of interest in this study was the presence of OAB. OAB was assessed using the					
142	Overactive Bladder Symptom Score (OABSS), a validated questionnaire developed in					
143	Japanese [18]. The OABSS is a self-reported questionnaire consisting of four domains					
144	(daytime frequency, 0-2 points; nighttime frequency, 0-3 points; urgency, 0-5 points;					
145	urgency incontinence, 0-5 points), with a total score of 15 points [18] A higher score					
146	indicates more severe OAB symptoms. Based on previous studies and decision modelling on					
147	HEEs, OAB was defined as an urgency score of $\geq 2$ points and a total score of $\geq 3$ points, and					
148	the severity of OAB was categorized as mild (OAB with a total score of $\leq$ 5 points) or					
149	moderate-to-severe (OAB with a total score of 6-15 points) [14].					
150						
151	Outcomes (health utility values)					
152	Our primary outcome of interest was HUVs measured using the EQ-5D-5L instrument.					
153	HUVs are an indicator of an individual's current health state, where 0 represents death or the					
154	worst imaginable health state and 1 represents perfect health, with higher scores indicating					
155	better health status [10]. In HEEs, HUVs are calculated using PBMs developed with choice					
156	methods (e.g. standard gambling or time trade-off) as reference standards [10, 11]. The					

157	EQ-5D-5L is a PBM developed by the EuroQoL Group that is used to measure HUVs based					
158	on time trade-off methods [10, 11]. Importantly, the EQ-5D-5L has been translated and					
159	validated in Japanese, demonstrating substantial reliability and validity for calculating HUVs					
160	in the general Japanese population [17].					
161	In this study, we used the EuroQoL Visual Analogue Scale (EQ VAS) score as					
162	another measure of health utility. The EQ VAS is a scale developed by the EuroQoL Group					
163	that measures the current health state using a VAS on a vertically oriented ruler with					
164	markings from 0 to 100 [17]. On the EQ-VAS, 0 represents death or the worst imaginable					
165	health state, and 100 indicates perfect health. The EQ VAS has often been used in					
166	conjunction with the EQ-5D in similar studies [14], and consistent results have been reported.					
167	Therefore, we used the EQ-VAS score as an outcome measure for sensitivity analysis in this					
168	study.					
169	This study used the online formats of the EQ-5D-5L and EQ VAS. The research					
170	protocol was pre-registered on the EuroQoL website [16], and permission was obtained to use					
171	these instruments. The online versions were administered in strict accordance with the					
172	manufacturers' instructions. The EuroQoL registration number for this study is 59331.					
173						
174	Covariates					
175	The covariates of interest in this study were demographic, socioeconomic, and health-related					
176	variables. These variables were selected from previous studies on OAB that focused on the					
177	factors that could potentially influence HUVs. The demographic factors included age					
178	(continuous), gender (male or female), and body mass index BMI (continuous).					
179	Socioeconomic status included educational attainment (high school education or less and					
180	college education or more) and income [6]. As a proxy for income, this study used equivalent					
181	household income, derived by adjusting total household income by the square root of					
182	household size (then grouped by median, with ranges provided: lower half, JPY 0-2.8					
183	million; upper half, JPY $\geq$ 2.9 million), along with a declined to answer category.					
184	Health-related factors included smoking status (never/past/current), alcohol consumption					
185	(never/past/current), and self-reported coexisting physical and psychiatric comorbidities.					

9

186 Comorbidity data were used to record the presence or absence of the following diseases:

187 hypertension, dyslipidemia, diabetes, low back pain, ischemic heart disease, stroke, chronic

188 kidney disease, stress urinary incontinence, depression, and other psychiatric disorders [5,

189 19–22].

190

191 Statistical analyses

192 This study used three analytical approaches. First, a primary analysis was performed targeting

all respondents. Second, subgroup analyses were performed, stratified based on sex

194 (male/female) and age (65–74 years old/≥75 years), assuming that the impacts of OAB on

195 HUVs may vary according to these factors. Third, an exploratory analysis was performed to

evaluate the impact of each of the four domains constituting the OAB on HUVs. In all

analyses, we initially described the baseline characteristics, including the prevalence of OAB

and HUVs. Subsequently, we described the mean (standard deviation [SD]) and median

199 (interquartile range [IQR]) of HUVs based on summary statistics for each group for all

analyses. Finally, we estimated the adjusted HUV decrements (disutilities) using a

201 multivariable linear regression analysis after adjusting for covariates. In the multivariable

202 linear regression analysis with ordinal categories (non-OAB/mild OAB/moderate-to-severe

203 OAB), a linear trend test was conducted to assess linearity. To confirm the consistency of the

results, a sensitivity analysis was performed in the primary analysis to fit a similar linear

regression model using the EQ VAS score as the outcome measure.

For all regression models,  $\beta$  coefficients, 95% confidence intervals (CIs), and *p*-values were calculated. Statistical significance was set at *p*<0.05. All analyses were performed using STATA version 18.0 (Stata Corp, College Station, Texas, USA).

209

210 *Ethical considerations* 

211 All respondents completed online questionnaires after providing digital informed consent

212 indicating their willingness to participate in the survey. Participants received monetary points

as an incentive for participation. All the procedures adhered to the ethical guidelines of the

214 1975 Declaration of Helsinki and its subsequent 2013 revision. This study was approved by

- 215 the Institutional Review Board of Keio University School of Medicine (approval number:
- 216 20221120). This study followed the Strengthening the Reporting of Observational Studies in
- 217 Epidemiology (STROBE) guidelines for cross-sectional studies.
- 218

219	Results

- 220 Baseline characteristics
- 221 Of the 1,099 respondents, 994 (90.7%) were included in the analysis (Figure 1). The median
- age of the participants was 73.2 (SD, 5.3) years, and 516 (51.9%) were male. Regarding
- socioeconomic indicators, 557 (56.0%) participants had college or higher education.
- 224 Regarding health-related factors, 107 (10.8%) participants were current tobacco users, 519
- 225 (52.2%) were current alcohol users, 486 (48.9%) had hypertension, 166 (16.7%) had diabetes,
- 226 114 (11.5%) had stress urinary incontinence, and 50 (5.0%) had depression. The mean
- 227 OABSS was 2.7 (SD, 2.2). The mean HUV was 0.90 (SD, 0.11), and the mean EQ VAS
- 228 score was 75.2 (SD, 17.6) (**Table 1**).
- 229
- 230 Health utility values based on overactive bladder status
- 231 Table 2 presents a summary of the HUVs stratified according to the presence and severity of
- 232 OAB. The mean HUV for participants without OAB was 0.913 (SD, 0.105), whereas that for
- those with OAB was 0.855 (SD, 0.145). When categorizing OAB severity into mild and
- 234 moderate-to-severe OAB, the mean HUV for participants with mild OAB was 0.874 (SD,
- 235 0.131), and for those with moderate-to-severe OAB, it was 0.840 (SD, 0.155).
- 236
- 237 Disutilities of overall respondents
- **Table 3** presents the results of the multivariable linear regression analyses. After adjusting
- for covariates, the estimated disutility for the presence of OAB was -0.0472 (95% CI,
- -0.0664 to -0.0279; p<0.001). The estimated disutilities for mild and moderate-to-severe
- 241 OAB were -0.0334 (95% CI, -0.0602 to -0.0066; *p*=0.014) and -0.0591 (95% CI, -0.0844 to
- -0.0339; p<0.001), respectively, indicating a linear relationship (p for trend<0.001). The
- 243 sensitivity analysis using the EQ VAS as the outcome variable showed similar results

244	(presence of OAB, $\beta$ =–5.42, 95% CI –8.47 to –2.37, <i>p</i> =0.001; mild OAB, $\beta$ =–4.36, 95% CI					
245	$-8.60$ to $-0.12$ , $p=0.044$ ; moderate-to-severe OAB, $\beta=-6.26$ , 95% CI $-10.26$ to $-2.27$ ,					
246	<i>p</i> =0.002; <i>p</i> for trend<0.001).					
247						
248	Results of the subgroup analysis					
249	Tables S1 and S2 present the baseline characteristics of the sex and age subgroups,					
250	respectively. Table S3 summarizes the HUVs for sex and age subgroups of HUVs. In the sex					
251	subgroup, regardless of the presence of OAB, females (n=478) had lower mean HUVs than					
252	males (n=516) (e.g. presence of any OAB: male, 0.872 [SD, 0.128]; female, 0.821 [SD,					
253	0.173]). In the age subgroup, regardless of the presence of OAB, the 75–94-year-old group					
254	(n=502) showed lower HUVs compared with the 65–74-year-old group (n=492) (e.g.					
255	presence of any OAB: 65-74 years old, 0.889 [SD, 0.130]; 75-94 years old, 0.829 [SD,					
256	0.152]).					
257	The results of the multivariable linear regression analysis are shown in Figure 2. In					
258	the gender subgroup, a substantial disutility was observed in females with moderate-to-severe					
259	OAB ( $\beta$ =-0.1026; 95% CI, -0.1510 to -0.0542; <i>p</i> <0.001). In the age subgroup, substantial					
260	disutilities were observed in the 75–94-year-old group with mild OAB ( $\beta$ =–0.0688; 95% CI,					
261	$-0.1106$ to $-0.0271$ ; p=0.001) and moderate-to-severe OAB ( $\beta$ = $-0.0664$ ; 95% CI, $-0.1006$ to					
262	-0.0322; <i>p</i> <0.001).					
263						
264	Results of the exploratory analysis					

Table S4 presents a summary of the HUVs for each domain and the score of the OABSS.

The higher OABSS scores indicated the lower mean HUVs in the three domains, excluding

urgency urinary incontinence. The results of the multivariable linear regression analysis after

rounding scores of <2.5% of the total are shown in Figure 3. After adjusting for covariates,

disutilities were observed for each score in the three domains, excluding daytime frequency

(e.g. nighttime frequency: 1 point,  $\beta = -0.0089$ , 95% CI -0.0276 to 0.0099, p = 0.035; 2 points,

 $\beta$ =-0.0193, 95% CI -0.0411 to 0.0025, p=0.082; 3 points,  $\beta$ =-0.0409, 95% CI -0.0682 to

-0.0136, p=0.003). A linear relationship between scores and disutilities was observed in all

12

273 domains, except for daytime frequency (p for trend: nighttime frequency, 0.003; urgency,

- 274 <0.001; and urgency incontinence, <0.001).
- 275
- 276

#### 277 Discussion

278 This study described the HUVs of Japanese adults aged  $\geq 65$  years with or without OAB and 279 estimated the associated disutility of OAB using regression models. The results demonstrated 280 that the mean HUVs of individuals with OAB were lower and the disutility of OAB was 281 greater, depending on the severity of the condition. Subgroup analyses suggested that females 282 and those aged 75 years might experience greater disutility owing to OAB than their 283 counterparts. Furthermore, exploratory analyses indicated the possibility of 284 score-proportional disutility in all domains of the OABSS, except daytime frequency. 285 Previous studies have evaluated the associations of OAB with HUVs in several 286 countries. Kay et al. conducted a study estimating EQ-5D-3L-based HUVs from the 287 Incontinence-Specific Quality of Life Questionnaire in 2,505 patients with idiopathic or 288 neurogenic OAB in the United States and Europe [12]. Similarly, Ruiz et al. used the 289 Overactive Bladder Symptom and Health-Related Quality of Life Questionnaire in 246 290 patients with OAB to estimate the effects of OAB symptoms on EQ-5D-3L-based HUVs in

Spain [13]. Additionally, Kim *et al.* assessed the effects of OAB severity as defined by the

**292** OABSS on EQ-5D-3L-based HUVs in 226,867 participants (including 12,303 patients with

OAB) from the 2012 Korean Community Health Survey [14]. These studies shared two

common features. First, they estimated the associations of OAB with HUVs using OAB

295 measures that are policy-relevant in their respective countries. Second, they employed the

EQ-5D-3L for evaluation. These factors significantly influenced the design of this study in a

297 Japanese setting. Second, regarding the choice of OAB measure, we used the OABSS, similar

to Kim *et al.*, as it is explicitly used to define OAB in the Japanese OAB guidelines [23]. The

299 OABSS was used to define OAB in a randomized controlled trial evaluating the effects of

300 OAB interventions in Japan [24]. Therefore, decision modelling based on the OABSS is

301 expected when conducting HEEs targeting patients with OAB in Japan. Second, we used the

13

302 EQ-5D-5L, for which a value set developed and validated by Ikeda *et al.* exists in Japan [17]. 303 Evidence suggests that the EQ-5D-3L may potentially overestimate positive associations and 304 underestimate negative associations compared with the EQ-5D-5L in HEEs [15]. 305 Consequently, the EO-5D-5L is recommended for cost-effectiveness evaluations in Japan 306 [25], and our study adhered to this recommendation. This study, which fully considers 307 Japanese clinical practices and healthcare systems, provides HUVs appropriate for HEEs in 308 the Japanese setting. We believe that our approach offers valuable insights for the design of 309 future studies in any country. 310 In this study, the disutility values for mild and moderate-to-severe OABs as defined 311 by the OABSS were -0.034 and -0.0591, respectively. When referring to the Japanese 312 population norms using the EQ-5D-5L, these disutilities are comparable to those of other 313 chronic conditions that affect HRQoL, such as allergic rhinitis (-0.027), atopic dermatitis 314 (-0.031), and other skin diseases (-0.043) [26]. In a report from Korea, which used the same 315 scale (OABSS) and criteria to define OAB as our study, the covariate-adjusted disutility 316 values for mild OAB, moderate OAB, and severe OAB were -0.029, -0.089, and -0.179, 317 respectively [14]. The smaller disutility for moderate-to-severe OAB in our study compared 318 to Kim *et al.*'s findings may be explained by differences in the mean age (75 years vs. 45.2 319 years), outcome measure (EQ-5D-5L vs. EQ-5D-3L), and ethnicity (Japanese vs. Korean). 320 However, both studies consistently showed that disutility increased with severity, 321 emphasizing the importance of the associations of OAB with HUVs. Furthermore, our study 322 found high disutility (-0.1026) among female participants with moderate-to-severe OAB in 323 the subgroup analyses. This finding may be supported by the results of EpiLUTS, an Internet 324 survey conducted among individuals aged >40 years in the United States, which showed that 325 a higher proportion of women (39.4%) than men (28.7%) reported moderate-to-severe 326 problems in their patient perception of bladder condition for OAB with bother [27]. 327 Additionally, in the subgroup of individuals aged  $\geq$ 75 years, mild and moderate-to-severe 328 OABs were associated with disutility values of similar magnitude (mild OAB -0.0688 vs. 329 moderate-to-severe OAB -0.0664). This finding suggests that the presence of OAB,

regardless of severity, may have a substantial impact on older adults who are more likely to

14

be frail than younger respondents. For example, evidence has shown that even in the absenceof incontinence, the presence of OAB is a significant risk factor for falls [28].

333 Our study has several strengths. First, we comprehensively provided the descriptive 334 and analytical information necessary for the HEE of OAB, specifically for older adults. The 335 mean and median HUVs at baseline and the disutilities after covariate adjustment for each 336 severity level of OAB are essential information when conducting HEEs. Second, this study 337 estimated disutility by adjusting for a wide range of evidence-based covariates, from 338 socioeconomic to health-related indicators. Third, a subgroup analysis was performed to 339 identify vulnerable populations that are essential for HEEs from the perspective of equity 340 considerations but are understudied [29]. Moreover, our subgroup analysis results provide 341 HUVs that can be referenced in future HEEs, particularly when treatments specifically 342 targeting nocturia or urgent urinary incontinence among the OAB symptoms become 343 available.

344 However, this study has also some limitations. First, as this study utilized an Internet 345 survey, there were concerns regarding the external validity of the results. However, the 346 prevalence of OAB (15.9%) and mean HUV (0.89) in this study did not substantially differ 347 from previous epidemiological data from Japan [26, 30]. Thus, these values are also expected 348 to apply to HEEs. Second, the sample size was limited (approximately 1,000); consequently, 349 there were few individuals with high scores on the OABSS (e.g. 2 points for daytime 350 frequency and 4–5 points for urgency urinary incontinence). As a result, it was not possible to 351 differentiate between moderate and severe OAB, and some scores were grouped in the 352 exploratory analysis. Although the number of individuals with such high scores may not be 353 large and may not be considered in actual HEEs, revalidation of our study with a larger 354 sample size would be valuable. Third, there may have been residual confounding factors. For 355 example, orthopedic factors, such as falls and fractures, can be considered in future models. 356 In conclusion, this study examined HUVs in older Japanese adults with and without 357 OAB. The results also demonstrated that increasing the severity of OAB indicated greater 358 disutility, highlighting the substantial effect of OAB on HRQoL. These findings serve as

- 359 valuable resources for future HEEs of OAB, possibly guiding decision-making in healthcare
- 360 resource allocation for policymakers.

# 362 Acknowledgments

- 363 This study was supported by the Japan Society for the Promotion of Science KAKENHI grant
- 364 (grant number: 21K17228) for conducting the survey. This study was also supported by the
- 365 National Institute of Public Health for the language editing fee and article publishing charge.
- 366

# 367 Conflicts of interest

- 368 TY has received the Japan Society for the Promotion of Science (JSPS) KAKENHI grant
- 369 (grant number: 21K17228) for conducting the survey. RG has received grants for the
- 370 evaluation of the cost-effectiveness of medicines and medical devices from the National
- 371 Institute of Public Health, Japan since 2019, which support the consultation fees for the
- development of search strategies and will support the article publication fee. KO, SF, and TM
- 373 have no conflicts of interest to declare. The funders did not participate in the study design,
- data collection, analysis, interpretation, manuscript preparation, review, approval, or decision
- to submit the manuscript for publication.
- 376

### 377 Data availability statement

- 378 The datasets generated and analyzed during the current study are available from the
- 379 corresponding author upon reasonable request.
- 380

## 381 References

382	1. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and
383	economic burden of urgency urinary incontinence: a systematic review. Eur Urol 2014;
384	65: 79–95.

- 2. Peyronnet B, Mironska E, Chapple C, *et al.* A comprehensive review of overactive bladder
  pathophysiology: on the way to tailored treatment. *Eur Urol* 2019; 75: 988–1000.
- 387 3. Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. *Res Rep Urol*388 2016; 8: 71–6.
- 389 4. Just KS, Schultze KA, Dormann H, et al. Use of overactive bladder anticholinergic

medications associated with falls leading to emergency department visits: results from
the ADRED study. *Eur J Clin Pharmacol* 2023; 79: 1185–93.

- 392 5. Durden E, Walker D, Gray S, Fowler R, Juneau P, Gooch K. The economic burden of
  393 overactive bladder (OAB) and its effects on the costs associated with other chronic,
  394 age-related comorbidities in the United States. *Neurourol Urodyn* 2018; 37: 1641–9.
- 395 6. Lin W, Li T, Xu Z, et al. Association of socioeconomic status and overactive bladder in
- 396 US adults: a cross-sectional analysis of nationally representative data. *Front Public*397 *Health* 2024; 12: 1345866.
- 398 7. Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women. *Mayo Clin*399 *Proc* 2020; 95: 370–7.
- 400 8. Project information | Vibegron for treating symptoms of overactive bladder ID6300 |
- 401 Guidance | NICE. [cited 2024 Jun 5]. Available from:
- 402 https://www.nice.org.uk/guidance/indevelopment/gid-ta11348.
- 403 9. Keam SJ. Vibegron: first global approval. *Drugs* 2018; 78: 1835–9.
- 404 10. Chang EM, Saigal CS, Raldow AC. Explaining health state utility assessment. JAMA

405	2020; 323:	1085–6.
-----	------------	---------

406	11. Foreword   Guide to the methods of technology appraisal, 2013. Guidance   NICE. [cited
407	2024 Jun 5]. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword.
408	12. Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D. Mapping EQ-5D utility
409	scores from the Incontinence Quality of Life Questionnaire among patients with
410	neurogenic and idiopathic overactive bladder. Value Health 2013; 16: 394-402.
411	13. Ruiz MA, Gutiérrez LL, Monroy M, Rejas J. Mapping of the OAB-SF questionnaire onto
412	EQ-5D in Spanish patients with overactive bladder. Clin Drug Investig 2016; 36:
413	267–79.
414	14. Kim SK, Kim SH. The impact of overactive bladder on health-related quality of life in
415	Korea: based on the results of a Korean Community Health Survey. Qual Life Res 2021;
416	30: 1017–24.
417	15. Wailoo A, Alava MH, Pudney S, et al. An international comparison of EQ-5D-5L and
418	EQ-5D-3L for use in cost-effectiveness analysis. Value Health 2021; 24: 568–74.
419	16. EuroQol [Internet], 2022 [cited 2024 Jun 10]. Available from:
420	https://euroqol.org/information-and-support/euroqol-instruments/eq-5d-5l/. Eq-5d-5l.
421	17. Ikeda S, Shiroiwa T, Igarashi A, et al. Developing a, Japanese version of the EQ-5D-5L
422	value set. J Natl Inst Public Health 2015; 64: 47–55.
423	18. Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder
424	syndromeoveractive bladder symptom score. Urology 2006; 68: 318–23.
425	19. Welk B, Baverstock R. Is there a link between back pain and urinary symptoms?
426	Neurourol Urodyn 2020; 39: 523–32.
427	20. Ceyhun G, Erbay G. Relationship between the severity of coronary artery disease and
428	overactive bladder. Acta Cardiol Sin 2021; 37: 254–60.

429	21. Lai S.	Pastore S.	Piloni L, et	t al. Chronio	c kidney	disease and	urological	disorders:
			- ,					

- 430 systematic use of uroflowmetry in nephropathic patients. *Clin Kidney J* 2019; 12: 414–9.
- 431 22. Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome:
- 432 evaluation and management. *Curr Urol* 2018; 11: 117–25.
- 433 23. The Japanese Continence Society, The Japanese Urological Association, eds. *Clinical*

434 *Guidelines for Overactive Bladder Syndrome*, 3rd edn, 2022.

- 435 24. Funada S, Luo Y, Uozumi R, *et al.* Multicomponent intervention for overactive bladder in
  436 women: A randomized clinical trial. *JAMA Netw Open* 2024; 7: e241784.
- 437 25. Center for Outcomes Research and economic evaluation for health, National Institute of

438 Public Health, 2024. Core to Evidence-Based Health, Policy [cited 2024 Jun 7].

- 439 Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance440 Medical Council. Available from:
- 441 https://c2h.niph.go.jp/tools/guideline/guideline\_en\_2024.pdf.
- 442 26. Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health
- 443 utilities index Mark 3: disutility catalog by disease and symptom in community settings.
- 444 *Value Health* 2021; 24: 1193–202.
- 27. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive
  bladder symptoms on health-related quality of life, anxiety, depression, and treatment
  seeking in the United States: results from EpiLUTS. *Urology* 2012; 80: 90–6.
- 448 28. Omae K, Kurita N, Takeshima T, et al. Significance of overactive bladder as a predictor
- of falls in community dwelling older adults: 1-year followup of the Sukagawa study. J *Urol* 2021; 205: 219–25.
- 451 29. Husereau D, Drummond M, Augustovski F, *et al.* Consolidated health economic
- 452 evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting
- 453 guidance for health economic evaluations. *Pharmacoeconomics* 2022; 40: 601–9.

- 454 30. Funada S, Kawaguchi T, Terada N, et al. Cross-sectional epidemiological analysis of the
- 455 Nagahama study for correlates of overactive bladder: genetic and environmental
- 456 considerations. *J Urol* 2018; 199: 774–8.

## 458 Tables

Variables	Category	n	%
Age	Mean (SD)	73.2	(5.3)
	Median [IQR]	75	[68–77]
Gender	Male	516	51.9
BMI	Mean (SD)	22.6	(3.4)
	Median [IQR]	22.3	[20.5–24.3]
Educational attainment	College graduate or more	557	56.0
Equivalent household income	Lower half	409	41.2
	Upper half	360	36.2
	Decline to answer	225	22.6
Smoking status	Never	477	48.0
	Past	410	41.3
	Current	107	10.8
Alcohol consumption	Never	246	24.8
	Past	229	23.0
	Current	519	52.2
Presence of comorbidities	Hypertension	486	48.9
	Dyslipidemia	407	41.0
	Diabetes	166	16.7
	Low back pain	566	56.9
	Ischemic heart disease	91	9.2
	Stroke	63	6.3
	Chronic kidney disease	36	3.6
	Stress urinary incontinence	114	11.5
	Depression	50	5.0
	Other psychiatric disorders	44	4.4
OABSS	Mean (SD)	2.7	(2.2)
	Median [IQR]	2	[1-4]
Health utility value	Mean (SD)	0.90	(0.11)
	Median [IQR]	0.89	[0.83–1]
EQ-VAS score	Mean (SD)	75.2	(17.6)
	Median [IQR]	80	[70–88]

### **459 Table 1** Baseline characteristics of respondents (n=994)

460 Note. BMI, body mass index; EQ VAS, EuroQol Visual Analogue Scale; IQR, interquartile range; LUTS,
 461 lower urinary tract symptom; OABSS, Overactive Bladder Symptom Scale; SD, standard deviation.

OAB severity <sup>*</sup>	n (%)	Mean utility value (SD)	Median utility value [IQR]
Non-OAB	836 (84.1)	0.913 (0.105)	0.894 [0.867–1]
Any OAB	158 (15.9)	0.855 (0.145)	0.885 [0.784–1]
Mild OAB	71 (7.1)	0.874 (0.131)	0.895 [0.823–1]
Moderate-to-severe OAB	87 (8.8)	0.840 (0.155)	0.844 [0.759–1]

Table 2 Prevalence of OAB and utility values among overall respondents

Note. IQR, interquartile range; OAB, overactive bladder; SD, standard deviation.

\*Mild OAB is defined as domain 3 (urgency) of overactive bladder symptom score (OABSS) $\geq 2$  and total score of  $3\leq$ OABSS $\leq 5$ , and moderate-to-severe OAB is defined as domain 3 of OABSS $\geq 2$  and total score of  $6\leq$ OABSS $\leq 15$ .

Variables	Category	β*	SE	95% CI	<i>p</i> -value	p for trend
	Main analysis (out	come measu	re: EQ-5D	-5L)		
Presence or absence of OAB						
	Non-OAB			Reference		Not applicable
	Any OAB	-0.0472	0.0098	-0.0664 to -0.0279	< 0.001	Not applicable
Based on OAB severity						
	Non-OAB			Reference		
	Mild OAB	-0.0334	0.0136	-0.0602 to -0.0066	0.014	< 0.001
	Moderate-to-severe OAB	-0.0591	0.0129	-0.0844 to -0.0339	< 0.001	
	Sensitivity analysis (	(outcome mea	asure: EQ	-VAS)		-
Presence or absence of OAB						
	Non-OAB			Reference		Not applicable
	Any OAB	-5.42	1.55	-8.47 to -2.37	0.001	Not applicable
Based on OAB severity						
	Non-OAB			Reference		
	Mild OAB	-4.36	2.16	-8.60 to -0.12	0.044	< 0.001
	Moderate-to-severe OAB	-6.26	2.04	-10.26 to $-2.27$	0.002	

**Table 3** Results of multivariable linear regression models in the main and sensitivity analyses

Note. EQ-5D-5L, the 5-level EuroQoL 5 dimensions version; EQ VAS, EuroQol Visual Analogue Scale; CI, confidence interval; OAB, overactive bladder; SE, standard error.

<sup>\*</sup>Adjusted for age, sex, body mass index, educational attainment, equivalent household income, smoking status, alcohol consumption, and presence of comorbidities (hypertension, dyslipidemia, diabetes, low back pain, ischemic heart disease, stroke, chronic kidney disease, stress urinary incontinence, depression, and other psychiatric disorders).

### **Figure legends**

Figure 1 Flow diagram of this study

Figure 2 Results of multivariable linear regression models in the subgroup analyses

<sup>\*</sup>Adjusted for age, gender, body mass index, educational attainment, equivalent household income, smoking status, alcohol consumption, and presence of comorbidities (hypertension, dyslipidemia, diabetes, low back pain, ischemic heart disease, stroke, chronic kidney disease, stress urinary incontinence, depression, and other psychiatric disorders).

Abbreviations: CI, confidence interval; OAB, overactive bladder.

Figure 3 Results of multivariable linear regression models in the exploratory analyses

<sup>\*</sup>Adjusted for age, gender, body mass index, educational attainment, equivalent household income, smoking status, alcohol consumption, and presence of comorbidities (hypertension, dyslipidemia, diabetes, low back pain, ischemic heart disease, stroke, chronic kidney disease, stress urinary incontinence, depression, and other psychiatric disorders).

Abbreviations: CI, confidence interval; OABSS, overactive bladder symptom score.





β* (95% CI)	p for trend
Reference -0.0369 (-0.0711 to -0.0026) -0.0440 (-0.0729 to -0.0150)	0.001
Reference -0.0259 (-0.0693 to 0.0174) -0.1026 (-0.1510 to -0.0542)	<0.001
Reference -0.0004 (-0.0349 to 0.0340) -0.0490 (-0.0869 to -0.0112)	0.027
Reference -0.0688 (-0.1106 to -0.0271) -0.0664 (-0.1006 to -0.0322)	<0.001

0.1

